<DOC>
	<DOCNO>NCT00440882</DOCNO>
	<brief_summary>Transforming Growth Factor-b1 ( TGF-b1 ) involve development acute lung injury fibroproliferation acute respiratory distress syndrome ( ARDS ) . Procollagen III Peptide ( PIIINP ) validate marker fibroproliferation . PIIINP associate death ARDS patient . The simultaneous change TGF-b1 PIIINP never study patient ARDS . The relationship TGF-b1 outcome ARDS unknown . The aim study analyse change TGF-b1 PIIINP ARDS show relationships TGF-b1 - PIIINP outcomes ARDS .</brief_summary>
	<brief_title>Changes Transforming Growth Factor b1 Procollagen III Patients With Acute Respiratory Distress Syndrome</brief_title>
	<detailed_description>Primary outcome : To analyse change Transforming Growth Factor b1 Procollagen III acute respiratory distress syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Complement Factor B</mesh_term>
	<criteria>ARDS PaO2/FIO2 &lt; 200 mmHg positive endexpiratory pressure ( PEEP ) ³ 5 cm H2O ARDS criterion less 24 hour Informed consent Pregnancy Chronic interstitial fibrosis lung diseases Hepatic chronic disease Neutropenia £1 G/l Corticosteroid ( 200 mg/day hydrocortisone equivalent , less 2 week inclusion ) Immunosuppressive therapy within last 30 day Participation investigational drug device study within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>